The Continuing Challenge of Designer Drugs
The Carlat Addiction Treatment Report, Volume 9, Number 6, September 2021
Marilyn A. Huestis, PhD
Senior fellow at the Institute on Emerging Health Professions, Thomas Jefferson University. Former Chief of the Chemistry and Drug Metabolism Section, IRP, National Institute on Drug Abuse (NIA).
Dr. Huestis has disclosed that she has received payment as a consultant for Dynacare Laboratories, which provides lab testing. Dr. Capurso has reviewed this article and found no evidence of bias in this educational activity.
Designer drugs is a catchall term for a large group of illicit substances that can have disparate effects. Dr. Huestis provides an in depth look at the current state of designer drugs, what clinicians should be wary of, and treatment options.